In addition, the expression of cardiac function biomarkers, NT-proBNP and hs-cTnT, increased in the DM group (P < 0.01), and empagliflozin treatment attenuated their expression (P < 0.01). This evidence concerns the gene TNNT2 and diabetes mellitus.